ReviewFrontiers in cell and developmental biology2026
Understanding cancer as a systemic disease through comprehension of neural stemness as the core property of cancer cell and the basic rules it dictates.
Review in Frontiers in cell and developmental biology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cancer is a systemic disease with multilayered complexity. Some theories/hypotheses have been proposed to explain cancer. They are successful in explaining certain aspects of cancer, but meet serious challenges in other aspects. Inappropriate understanding of cancer cell and cancer complexity also hinders the development of more effective strategies of cancer therapy. My previous studies demonstrated that the core property of cancer (tumorigenic) cells is neural stemness. The finding led to the subsequent discovery about the central role of neural stemness during tumorigenesis and a paradigm that can hopefully explain systemic complexity of cancer as a whole. In the review, I summarize the evidence from research of evolutionary, developmental and cancer biology supporting that neural stemness, representing the general stemness predestined by its evolutionary advantage, determines both pluripotency and tumorigenicity, the key cellular properties underlying developmental and cancer biology, respectively. I made detailed discussions about the central role of neural stemness in understanding the core property and phenotypic traits of cancer cell and in understanding phenotypic heterogeneity in cancer. These pieces of evidence and discussions reveal that cancer is the manifestation of the power of basic rules dictating both embryogenesis and tumorigenesis. Briefly, acquiring neural stemness, hence a pluripotent state in ectodermal cells during embryogenesis, leads to neural development and body axis formation, i.e., embryonic neural induction, and ectopic neural induction causes a conjoined twin (secondary body axis); whereas acquirement of neural stemness, hence a pluripotent state in cells of a postnatal animal/human, results in a degenerated conjoined twin-like structure, i.e., a tumor. Tumors as conjoined twin-like structures formed in postnatal animals/humans helps understand the complex crosstalks within tumors and crosstalks between tumors and hosts. Moreover, neural stemness being the core property of cancer cell should account for the inverse correlation between cancer and neurodegeneration, and the neurodegeneration effect in patients after cancer therapies. Due to the central role of neural stemness in contributing to tumorigenesis, novel strategies of cancer therapy can be developed by targeting neural stemness using the principle of pluripotent cell differentiation. In addition, some essential issues worth considering in cancer research are also discussed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.